Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of TD-9855 to Treat Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* • American College of Rheumatology (ACR) Diagnostic Criteria for Fibromyalgia (FM)~  * Informed consent~ * 18 to 65 years of age~ * Discontinue therapy with adrenergic-acting drugs, and certain other medications~    * Only acetaminophen or NSAID as rescue pain medication~   * No narcotic pain meds or benzodiazepines~   * Only non-benzodiazepines as rescue hypnotics~Exclusion Criteria:~* Any current psychiatric disorder, lifetime bipolar disorder, severe comorbid Axis II disorder, mental retardation, etc, as assessed by Mini International Neuropsychiatric Interview (MINI)~* Major depression at screening by MINI when unable to be washed out of MDD meds (investigator or provider's judgment)~* Risk of suicide (investigator opinion and/or C-SSRS)~* Recent history of substance or alcohol abuse~* BMI \<18 or ≥45~* Concurrent disease; pain for diagnosed illness other than FM; non-compliance; history of seizures; pheochromocytoma; glaucoma; CV disease; orthostatic hypotension or orthostatic tachycardia; untreated sleep apnea~* Abnormal lab values (liver, kidney, thyroid, and others)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TD-9855 Group 1 (Type: EXPERIMENTAL): Group 1 to be dosed with TD-9855
- TD-9855 Group 2 (Type: EXPERIMENTAL): Group 2 to be dosed with TD-9855
- Placebo (Type: PLACEBO_COMPARATOR): Group to be dosed with Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).